Seelos Therapeutics, Inc. (SEEL): Price and Financial Metrics
GET POWR RATINGS... FREE!
SEEL Stock Price Chart Interactive Chart >
SEEL Price/Volume Stats
| Current price | $0.81 | 52-week high | $1.52 |
| Prev. close | $0.81 | 52-week low | $0.48 |
| Day low | $0.80 | Volume | 187,400 |
| Day high | $0.83 | Avg. volume | 460,881 |
| 50-day MA | $0.88 | Dividend yield | N/A |
| 200-day MA | $0.87 | Market Cap | 86.91M |
Seelos Therapeutics, Inc. (SEEL) Company Bio
Seelos Therapeutics, Inc. operates as a biotechnology company. The Company develops treatments for post-traumatic stress and major depressive disorders. Seelos Therapeutics serves patients in the United States.
Latest SEEL News From Around the Web
Below are the latest news stories about SEELOS THERAPEUTICS INC that investors may wish to consider to help them evaluate SEEL as an investment opportunity.
Seelos Therapeutics to Participate in the 12th Annual LifeSci Partners Corporate Access EventSeelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 12th Annual LifeSci Partners Corporate Access Event, to be held in San Francisco, California on January 9-11th, 2023. |
Parkinson's Study Using CRISPR Technology Shows Promise, Seelos Therapeutics SaysSeelos Therapeutics Inc (NASDAQ: SEEL) announced in vivo data demonstrating that a single dose of SLS-004 downregulated the production of alpha-synuclein (α-synuclein). This reduction of α-synuclein by SLS-004 in an established α-synuclein overexpressing animal model of Parkinson's disease (PD) resulted in a substantial increase and recovery of degeneration in tyrosine hydroxylase positive (TH+) dopaminergic neurons. TH+ dopaminergic neurons in the midbrain region, called substantia nigra pars c |
Seelos Therapeutics Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's DiseaseSeelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced in vivo data demonstrating that a single dose of SLS-004 downregulated the production of alpha-synuclein (α-synuclein). This reduction of α-synuclein by SLS-004 in an established α-synuclein overexpressing animal model of Parkinson's disease (PD) resulted in substantial increase and recovery of degener |
Seelos Therapeutics Releases the Itinerary for its Research and Development Update Conference Call and Webcast to be Held on December 15, 2022Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today released the itinerary for its research and development update conference call and webcast to be held on Thursday, December 15th from 1pm to 3pm ET. |
Seelos Therapeutics to Hold a Research and Development Update Conference Call and Webcast on December 15, 2022Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will hold a research and development update conference call and webcast on Thursday, December 15th from 1pm to 3pm ET. |
SEEL Price Returns
| 1-mo | 17.39% |
| 3-mo | -7.68% |
| 6-mo | -18.99% |
| 1-year | -28.95% |
| 3-year | -17.35% |
| 5-year | -98.78% |
| YTD | 19.29% |
| 2022 | -58.34% |
| 2021 | 3.16% |
| 2020 | 17.91% |
| 2019 | -76.74% |
| 2018 | -89.57% |
Loading social stream, please wait...